NCT00087412View on ClinicalTrials.gov

S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

July 31, 2007

Conditions
Adenocarcinoma of the LungLarge Cell Lung CancerRecurrent Non-small Cell Lung CancerSquamous Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer
Interventions
DRUG

erlotinib hydrochloride

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

78245

Southwest Oncology Group, San Antonio

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00087412 - S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter